The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.

"Declarations Competing interestsM.E. has received consulting fees from Merck; M.M. has received consulting fees from Bayer, Fresenius, Novartis, and Windtree Therapeutics for participation to advisory boards or executive committees of clinical trials; M.S. has received consulting fees from Bayer, Merck, Novartis, Vifor Farma, Abbott, Boehringer Ingelhein, AstraZeneca, Bioventrix, Servier; M.E. and M.S. are the Italian national leader investigators of VICTORIA. The other authors declare no competing interests. Competing interests M.E. has received consulting fees from Merck; M.M. has received consulting fees from Bayer, Fresenius, Novartis, and Windtree Therapeutics for participation to advisory boards or executive committees of clinical trials; M.S. has received consulting fees from Bayer, Merck, Novartis, Vifor Farma, Abbott, Boehringer Ingelhein, AstraZeneca, Bioventrix, Servier; M.E. and M.S. are the Italian national leader investigators of VICTORIA. The other authors declare no competing interests."

"Funding Open access funding provided by Scuola Superiore Sant'Anna within the CRUI-CARE Agreement."